Desktop Site
|
19 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,088.33
+599.34
+0.83 %
Corporate Announcement
Security Code
532523
Company
Biocon Ltd
Exchange Received Time
20/09/2019 18:49:43
Exchange Disseminated Time
20/09/2019 18:49:51
Time Taken
00:00:08
U.S. FDA Completes Pre-Approval Inspection Of Two New Biocon Biologics Facilities In Bengaluru |
9/20/2019 6:49:44 PM
"The U.S. FDA conducted a Pre-Approval Inspection (PAI) at two of our new Biologics Manufacturing facilities in Bengaluru from Sep 10 to Sep 19, 2019. The inspection included a new Drug Substance (DS) and a Drug Product (DP) unit.
At the conclusion of the inspection we received a Form 483 with four observations for the new DS facility, three observations for the new DP facility and one general observation. We are confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously. The Pre-Approval Inspection of our new facilities does not have any impact on our current commercialization plans from our existing facilities.' - Company Spokesperson
Attachment
<< Back
Recently Viewed